Could a wearable sensor replace fingerstick tests in the ICU?

NCT ID NCT07687368

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial compares continuous glucose monitoring (CGM) with standard fingerstick testing in 400 critically ill ICU patients with high blood sugar. CGM uses a small sensor under the skin to measure glucose every 5 minutes and alerts staff when levels are too high or low. The goal is to see if CGM helps keep glucose in a safe range, reduces dangerous highs and lows, and cuts down on the number of blood tests needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Continuous Glucose Monitoring (CGM) device
What this could lead to
If it works, CGM could become routine in ICUs, improving patient safety and reducing the need for frequent fingerstick blood tests.
What could go wrong
This is a single-center trial, and results may not apply to all ICUs. CGM may not significantly improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS GLUCOSE MONITORING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carrer de Villarroel, 170

    Barcelona, Catalonia, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.